{"filing":{"accession_number":"0001193125-26-251394","cik":"0001680581","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"fulc-20260601.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm"},"events":[{"id":7799,"run_id":6845,"accession_number":"0001193125-26-251394","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Fulcrum announced discontinuation of its pociredir program for sickle cell disease and initiation of a comprehensive strategic review. While this represents a material operational change affecting the company's pipeline and strategic direction, it does not fit neatly into more specific categories (not a restatement, impairment charge, going-concern disclosure, or M\u0026A activity per se). The strategic review language suggests potential future M\u0026A or restructuring, but the disclosed event itself is the program discontinuation and review initiation.","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3140,"accession_number":"0001193125-26-251394","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Fulcrum announced discontinuation of its pociredir program for sickle cell disease and initiation of a comprehensive strategic review. While this represents a material operational change affecting the company's pipeline and strategic direction, it does not fit neatly into more specific categories (not a restatement, impairment charge, going-concern disclosure, or M\u0026A activity per se). The strategic review language suggests potential future M\u0026A or restructuring, but the disclosed event itself is the program discontinuation and review initiation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:39:38.736474+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3140,"accession_number":"0001193125-26-251394","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Fulcrum announced discontinuation of its pociredir program for sickle cell disease and initiation of a comprehensive strategic review. While this represents a material operational change affecting the company's pipeline and strategic direction, it does not fit neatly into more specific categories (not a restatement, impairment charge, going-concern disclosure, or M\u0026A activity per se). The strategic review language suggests potential future M\u0026A or restructuring, but the disclosed event itself is the program discontinuation and review initiation.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:39:38.736474+00:00","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-06-01"}]}